Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Independent

Published November 12, 2026 · Updated November 13, 2026

Trump team funds controversial psychedelic ibogaine for veteran PTSD study

Read the full story at Independent

Derived from a West African shrub, ibogaine can cause intense hallucinations, nausea, vomiting, tremors, and severe heart rhythm issues.

Surfaced by 3 Google Alerts

  • Ibogaine
  • Psychedelics europe
  • Psychedelics middle east